PHARMACY

Mylan distribution center receives VAWD accreditation

BY Alaric DeArment

PITTSBURGH A Mylan distribution center has received Verified-Accredited Wholesale Distributors accreditation from the National Association of Boards of Pharmacy, the generic drug maker announced Tuesday.

Mylan drugs constitute one-in-12 branded and generic prescriptions dispensed in the United States, according to IMS Health, and the company distributes most of its drugs from the center, in Greensboro, N.C. The NABP established the VAWD program in 2004 as a way of certifying companies that keep counterfeit drugs out of the drug supply.

“This accreditation provides further reassurance to our valued customers that Mylan’s products are of the highest quality and are safeguarded against counterfeit and fraud,” Mylan North America president Hal Korman stated.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA approves expanded use of Crestor

BY Alaric DeArment

WILMINGTON, Del. The Food and Drug Administration has approved a new use for a cardiovascular drug made by AstraZeneca, the drug maker announced Monday.

The FDA approved Crestor (rosuvastatin calcium) for reducing the risk of stroke, heart attack and surgical restoration of blood flow – known as arterial revascularization – in patients without obvious coronary heart disease but an increased risk of cardiovascular disease based on age, presence of risk factors for cardiovascular disease and quantities of high-sensitivity C-reactive protein in the blood of 2-mg per liter or more. Crestor already had approval for treating other cardiovascular health risks when used along with changes in diet.

“Not only is this approval a significant milestone for AstraZeneca, but it is also important for the patients who could now benefit from Crestor therapy under this approved indication,” AstraZeneca chief medical officer Howard Hutchinson stated.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

CMS: U.S. health spending hits $2.5 trillion as Rx costs reach $246 billion

BY Jim Frederick

WASHINGTON Healthcare spending in the United States climbed 5.7% to $2.5 trillion in 2009, despite the impact of a struggling economy, according to projections issued by the Centers for Medicare and Medicaid Services and published in the journal Health Affairs.

Healthcare expenditures now comprise 17.3% of the nation’s total gross domestic product, CMS estimated. Over the next decade, the agency predicted, health spending will jump at an average rate of 6.1% a year, versus a projected average annual gain of 4.4% for the overall GDP.

With more Americans losing their insurance and Medicaid enrollments rising, public spending for health care will continue to grow faster than health spending in the private sector, the government predicted.

The rise in total health costs was not quite matched by the growth of prescription drug spending, CMS economists estimated. Total prescription drug spending rose a projected 5.2% last year, the agency reported in Health Affairs, to a U.S. total of $246.3 billion.

That marks an accelerating trend for drug spending, according to the journal, which cited “an increase in per person use of drugs, driven by the need for antiviral drugs to treat H1N1, and by higher price growth in brand-name drugs.”

Long-term growth of both overall healthcare expenditures and the prescription drug market will continue at a steady clip, government analysts predict. CMS pegs total drug expenditures at $457.8 billion by 2019, Health Affairs reported, “with spending growth expected to accelerate over the projection period due primarily to increases in drug prices.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES